Arie Belldegrun

Last updated
Arie S. Belldegrun
Born1949 (age 74–75)
Tel Aviv, Israel
CitizenshipIsraeli
American
Alma mater Hadassah Medical Center
Weizmann Institute of Science
Years active1988–present
Known forFounder of Kite Pharma
Spouse Rebecka Belldegrun
Children4
Relatives Poju Zabludowicz (brother-in-law)
Anita Zabludowicz (sister-in-law)

Arie S. Belldegrun (born 1949), FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

Contents

Early life and education

Belldegrun was born in Tel Aviv, Israel. [1] He received his medical degree from the Hadassah Medical Center at Hebrew University of Jerusalem in 1974, and conducted his post-graduate studies at the Weizmann Institute of Science in 1979. [2] He completed his urologic surgery residency at Harvard Medical School in 1985, and his Surgical Oncology fellowship at the National Cancer Institute in 1988. [2] He is certified by the American Board of Urology, and is a fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. [3] [4] Belldegrun is the director of the UCLA Institute of Urologic Oncology, professor of urology, and chief of the Division of Urologic Oncology at the David Geffen School of Medicine. [5] [6] [7]

Career

In 1996, Belldegrun established his first company, Agensys, which was an early-stage privately held biotechnology company based in Los Angeles. The company was focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets. He served as its founding chairman of the board of directors from 1996 to 2002, and then as a director. [8] In December 2007, Agensys was acquired by Astellas Pharma in a deal valued at US$537 million. [9] [10]

In 2003, Belldegrun became the founding vice-chairman of the board of directors and chairman of the scientific advisory board of Cougar Biotechnology; the company had a focus in the field of oncology. In July 2009, Cougar Biotechnology was acquired by Johnson & Johnson in a $970 million transaction. In April 2011, the United States Food and Drug Administration approved abiraterone acetate (Zytiga), Cougar's lead product, for late-stage prostate cancer. [11] [12]

In 2008, Belldegrun became the chairman and partner of Two River, a New York-based venture capital firm and merchant bank focused on the life science sector. Two River specializes in investments in life science, biotechnology, and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease, neurological disorders, and companion animal health care. [13]

Belldegrun is the founder, chairman, president and CEO of Kite Pharma. Although founded in 2009, the company went public in June 2014. Based in Santa Monica, Kite Pharma is a commercial-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T cell therapy (eACT) designed to restore the immune system's ability to recognize and eradicate tumors. [14] On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, [15] equating to $180 cash per share. The deal added a CAR-T candidate to Gilead's existing portfolio. [16] The acquisition was completed in October 2017. [17] In October 2017, Kite Pharma's therapy, Yescarta (axicabtagene ciloleucel) became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. [18]

In 2017, Belldegrun became the co-founder and senior managing director of Vida Ventures, a Boston-based life sciences investment firm that consists of scientists, physicians, entrepreneurs, and investors passionate about building and funding breakthroughs in biomedicine. Vida Ventures has a bicoastal presence. [19] [20] [21] In June 2021, Vida Ventures closed its third fund (Vida Ventures III) with $825 million. Vida Ventures currently has approximately $1.7 billion in assets under management. [22]

In 2017, Belldegrun co-founded and serves as the executive chairman of Allogene Therapeutics, a San Francisco-based biotechnology company. Allogene has raised $300 in Series A fundraising, and $120 million in a private financing round. [23] [24] [25] On October 11, 2018, Allogene Therapeutics raised $324 million in an initial public offering on the NASDAQ, listing under the ticker "ALLO". [26] [27]

In July 2019, it was reported that Bellco Capital, Belldegrun's family office, has entered into a joint venture with Tishman Speyer to start Breakthrough Properties. Belldegrun serves as the co-chairman, while his son, Dan, is the company's CEO. The company purchased its first property in Boston's Seaport District for $80 million. [28] [29] In November 2020, Breakthrough Properties closed its first fund (Breakthrough Life Science Property Fund) with $1 billion. [30]

In May 2021, it was reported that Belldegrun's Bellco Capital is co-sponsoring the $2.5 billion merger of Ginkgo Bioworks with Soaring Eagle Acquisition Corp. (a SPAC), with a pre-money valuation of $15 billion. [31] [32] Ginkgo Bioworks is now trading on the NYSE under the ticker "DNA". Belldegrun serves on the board of directors of Ginkgo Bioworks.

Belldegrun also serves on the board of directors of Kronos Bio, Fosun Kite, UroGen Pharma, Pontifax, ByHeart and IconOVir Bio. [33] In the past, he served on the board of directors of Teva Pharmaceuticals, Cell Design Labs, Arno Therapeutics, SonaCare Medical, Roei Medical Technologies, Oncura, Nile Therapeutics, Hana Biosciences, Paramount Acquisition Corp and Chem Rx Corp. [33]

Personal life

Belldegrun is married to Rebecka Belldegrun and together they have four children. [6] They reside in Bel Air, Los Angeles. [34]

In 2014, according to the Bloomberg Pay Index, Belldegrun was ranked the 8th highest-paid executive in the United States, with a pay package valued at $95.2 million. [35] In 2015, The Hollywood Reporter's annual Hollywood's Top Doctors list included Belldegrun as one of the highest-rated urologists. [36]

In 2021, in its annual ranking of the wealthiest people in Israel, Forbes Israel ranked Arie and Rebecka Belldegrun 36th with a personal net worth of $1.75 billion. [37] They have donated over $1 million to the University of Pennsylvania School of Arts and Sciences, [38] and have donated a $5 million sculpture to LACMA. [39] [40]

Belldegrun was featured in the 2017–2021 editions of the LA500-LA's Most Influential People, compiled by the Los Angeles Business Journal , [41] and has been named Business Leader of the Year for 2018 in the Health Care category for a life dedicated to finding cures for cancer. [42] He was also featured in the CEO Today USA Awards 2017 which celebrate the success, innovation and strategic vision of CEOs across a number of sectors, industries within the US, identifying the most successful, innovative and forward-thinking CEOs in business today. [43] In June 2018, Belldegrun received the EY Master Entrepreneur Award at the Entrepreneur of the Year 2018 Awards. [44]

Belldegrun has written over 500 scientific publications related to urologic oncology and has authored several books on prostate and kidney cancers. [45] [46] He was one of the speakers at the Milken Institute Global Conference 2013, [47] delivered the keynote Andrew C. Novick Memorial Lecture at the Ninth International Kidney Cancer Symposium, [48] and regularly presents at the Annual J.P. Morgan Healthcare Conference. [49] It was announced that Belldegrun will present at the 34th Annual J.P. Morgan Healthcare Conference in January 2016. [50]

Belldegrun serves as a member of the advisory board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania [51] and as a member of the strategic advisory group of the Parker Institute for Cancer Immunotherapy. [52]

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd..

<span class="mw-page-title-main">David Geffen School of Medicine at UCLA</span> Medical school of UCLA

The University of California, Los Angeles School of Medicine, also known as the David Geffen School of Medicine at UCLA (DGSOM), is an accredited medical school located in Los Angeles, California, United States. Founded in 1951, it is the second medical school in the University of California system, after the UCSF School of Medicine. The school was renamed in 2001 in honor of media mogul David Geffen who donated $200 million in unrestricted funds.

Christoph Westphal is an American biomedical businessman.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnology startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located. Atlas raised its thirteenth fund totaling $450 million in March 2022, after raising its Opportunity Fund II totaling $300 million in September 2021.

Rebecka Belldegrun, is a Finnish-born Israeli-American ophthalmologist, billionaire businesswoman and investor.

Two River Group Holdings is a New York-based venture capital firm and merchant bank focused on the life science sector. It specializes in investments in life science, biotechnology, and in firms focused on developing preventive and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease, neurological disorders, and companion animal health care.

<span class="mw-page-title-main">James S. Economou</span> American physician (born 1951)

James S. Economou is an American physician-scientist on the faculty of the University of California, Los Angeles (UCLA) where he is also a surgical oncologist and tumor immunologist. He was Vice Chancellor for Research at UCLA (2010-2015) where he promoted academic entrepreneurship, transdisciplinary research, and support of the humanities, arts, and social sciences. The UCLA research enterprise generates almost one billion dollars in extramural funds annually.

Kite Pharma is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

<span class="mw-page-title-main">OS Fund</span> American venture-capital fund

OS Fund is an American venture capital fund that invests in early-stage science and technology companies.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

<span class="mw-page-title-main">Gregory L. Verdine</span> American chemical biologist

Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.

Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

<span class="mw-page-title-main">William Rastetter</span> American scientist, entrepreneur and venture capitalist

William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He was a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Iambic Therapeutics. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.

Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

References

  1. ↑ Bartholomew, Dana (23 March 2018). "Professor as Entrepreneur: UCLA's Belldegrun on to Next Biopharma Enterprise". Los Angeles Business Journal . Retrieved 10 May 2020.
  2. 1 2 "Curriculum Vitae", InfoFAQ, July 2007. Retrieved on 22 June 2013.
  3. ↑ "Dr. Arie S. Belldegrun, MD, FACS Joins Two River Group Holdings as Chairman and Partner". Reuters. 29 April 2008. Retrieved 25 June 2013.
  4. ↑ "Arie Belldegrun, MD" Archived July 15, 2013, at the Wayback Machine , UCLA Health. Retrieved on 25 June 2013.
  5. ↑ "Arie Belldegrun, M.D.", David Geffen School of Medicine. Retrieved on 25 June 2013.
  6. 1 2 "Arie Belldegrun, M.D.", USRF. Retrieved on 23 June 2013.
  7. ↑ "Advisory Board", Penn LSM. Retrieved on 28 August 2013.
  8. ↑ "Arie Belldegrun, M.D. ". Vagelos Program in Life Sciences & Management. Retrieved 29 November 2020.
  9. ↑ Moster, Roxanne & Champeau, Rachel (27 November 2007). "UCLA scientists' biotech firm to be acquired by pharmaceutical corp." Archived 2013-11-13 at the Wayback Machine . UCLA Newsroom. Retrieved 25 June 2013.
  10. ↑ "Board of Directors" Archived June 30, 2013, at the Wayback Machine , Nile Therapeutics. Retrieved on 25 June 2013.
  11. ↑ "Johnson & Johnson Completes Acquisition of Cougar Biotechnology" Archived November 1, 2012, at the Wayback Machine . Cougar Biotechnology. 10 July 2009. Retrieved 25 June 2013.
  12. ↑ "Board of Directors", Arno Therapeutics. Retrieved on 25 June 2013.
  13. ↑ "Company Overview of Two River Group Holdings, LLC", Businessweek. Retrieved on 26 June 2013.
  14. ↑ "About Kite Pharma" Archived January 21, 2015, at the Wayback Machine . Kite Pharma. Retrieved 21 January 2015.
  15. ↑ Reuters
  16. ↑ "Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy". fiercepharma.com. 2017-08-28. Retrieved 2017-08-29.
  17. ↑ "Gilead | Investors | News Release". investors.gilead.com. Retrieved 2017-10-29.
  18. ↑ "Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy". Gilead. 18 October 2017. Retrieved 24 December 2017.
  19. ↑ Stendahl, Max (15 December 2017). "Vida Ventures, Boston’s newest healthcare VC firm, unveils $255M fund". Boston Business Journal. Retrieved 24 December 2017.
  20. ↑ Densford, Fink (18 December 2017). "Boston VC firm Vida Ventures unveils $255m healthcare fund". Mass Device. Retrieved 24 December 2017.
  21. ↑ "Vida Ventures Unveils Next-Generation Life Sciences Venture Firm with $295 Million Under Management and an Investment in Allogene Therapeutics". BusinessWire. 3 April 2018. Retrieved 3 April 2018.
  22. ↑ "Life sciences venture capital firm Vida Ventures raises $825 million". Reuters. 24 June 2021. Retrieved 26 October 2021.
  23. ↑ Herper, Matthew (3 April 2018). "They're Back! After Selling Kite, Belldegrun And Chang Seek To Change Cancer Treatment Again". Forbes. Retrieved on 3 April 2018.
  24. ↑ Carroll, John (3 April 2018). "Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization". Endpoint News. Retrieved on 3 April 2018.
  25. ↑ Taylor, Phil (6 September 2018). "Allogene raises another $120M for off-the-shelf CAR-T programs". FierceBiotech. Retrieved 12 October 2018.
  26. ↑ Nisen, Max (11 October 2018). "Allogene’s Monster Biotech IPO Defies Market Rout". Bloomberg. Retrieved 12 October 2018.
  27. ↑ Mukherjee, Sy (11 October 2018). "Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO" Fortune. Retrieved 12 October 2018.
  28. ↑ McDonald, Michael & Katz, Lily (16 July 2019). "Doctor Who Sold $12 Billion Drug Firm Eyes Biotech Property". Bloomberg. Retrieved 16 July 2019.
  29. ↑ "Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-of-Its-Kind Global Life Sciences Real Estate Platform". BusinessWire. 16 July 2019. Retrieved 16 July 2019.
  30. ↑ "Breakthrough Properties Raises $1 Billion for Life Science Real Estate Investments". PR Newswire. 23 November 2020. Retrieved 29 November 2020.
  31. ↑ Feldman, Amy & Knapp, Alex. "Ginkgo Bioworks To Go Public In $17.5 Billion Deal With Former Hollywood Exec Harry Sloan’s SPAC". Forbes. 11 May 2021. Retrieved 26 October 2021.
  32. ↑ Paul Taylor, Nick. "Ginkgo lands on NYSE via SPAC merger, gaining $2.5B to fuel growth". FierceBiotech. 11 May 2021. Retrieved 26 October 2021.
  33. 1 2 "Arie S Belldegrun". Bloomberg. Retrieved 26 October 2021.
  34. ↑ "Architecture Project Entries 2003", AIANY, 2003. Retrieved on 23 June 2013.
  35. ↑ Melin, Anders & Chen, Caroline (11 June 2015). "Biotech CEOs among highest-paid US execs". Telegram.com. Retrieved 7 July 2015.
  36. ↑ "Hollywood's Top Doctors 2015: Best Urologists in Los Angeles". The Hollywood Reporter . 27 August 2015. Retrieved 15 June 2018.
  37. ↑ "עשירי ישראל 2021" (in Hebrew). Forbes . 25 July 2021. Retrieved 26 October 2021.
  38. ↑ "$1M Lifetime Donors to the School of Arts and Sciences". University of Pennsylvania. 30 June 2012. Retrieved 17 June 2016.
  39. ↑ "Smoke | LACMA Collections". LACMA. Retrieved 17 June 2016.
  40. ↑ "Tony Smith's monumental sculpture 'Smoke' will not disappear from LACMA; multimillion-dollar purchase finalized". Los Angeles Times. 18 June 2010. Retrieved 17 June 2016.
  41. ↑ "LA 500: Arie Belldegrun". Los Angeles Business Journal. 31 May 2021. Retrieved 26 October 2021.
  42. ↑ Lawrence, Carol (23 March 2018). "Laurels for Leaders: Aecom Boss Burke Highlights Class of Annual Honorees". Los Angeles Business Journal. Retrieved on 3 April 2018.
  43. ↑ "CEO Today USA Awards 2017". CEO Today. 2018. Retrieved 22 February 2018.
  44. ↑ "UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award". GlobeNewswire. 13 June 2018. Retrieved 15 June 2018.
  45. ↑ "Nile Therapeutics Appoints Arie S. Belldegrun, M.D., to Board of Directors". Reuters. Retrieved 13 November 2013.
  46. ↑ "US HIFU Appoints Arie Belldegrun, M.D. to Board of Directors". Reuters. Retrieved 13 November 2013.
  47. ↑ "Global Conference 2013" Archived November 13, 2013, at the Wayback Machine . Milken Institute. Retrieved 13 November 2013.
  48. ↑ "Medical Symposia Keynote Addresses" Archived November 13, 2013, at the Wayback Machine . Kidney Cancer Association. Retrieved 13 November 2013.
  49. ↑ "Kite Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference". BizJournals (Charlotte). 7 January 2014. Retrieved 26 May 2014.
  50. ↑ "Kite Pharma to Present at the 34th Annual J.P. Morgan Healthcare Conference". NASDAQ. 6 January 2016. Retrieved 6 January 2016.
  51. ↑ "Advisory Board". University of Pennsylvania. Retrieved 1 December 2020.
  52. ↑ "Arie Belldegrun, MD, FACS". Two River. Retrieved 1 December 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.